Linnaeus Therapeutics Announces First Patient Dosed in Its Phase 1/2 Clinical Trial of LNS8801 in Patients with Advanced Cancer Company Commences First-in-Human Study at Multiple Academic Sites in United States Haddonfield NJ,October 29, 2019--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development [...]